Use access key #2 to skip to page content.
$3.46 -0.19 (-5.21%)
5/16/2008 3:41 PM

XTENT, Inc. (XTNT)

CAPS Rating:
*

A development stage medical device company, which focused on developing and commercializing its customizable drug eluting stent systems for the treatment of coronary artery disease or CAD.

View All Commentary (XTNT)

Recs

0

Avatar Hopper39 (< 20) Submitted: 10/24/07 11:26 AM : Outperform Start Price: $9.75 XTNT Score: -59.69

Customizable drug eluting stent (DES) system targeting treatment of coronary artery disease (CAD), the most common form of cardiovascular disease and the number 1 cause of death in Europe and the United States.

Per recent BW article, Chase estimates that sales of drug-coated stents are a $4.1B industry in 2007.


Lots of pessimism built into the stock with stent business currently under scrutiny - JNJ and Boston Scientific have seen significant decline in their respective divisions. However, XTNT has shown positive 2 year and 1 year-out data in their Custom I and II clinical trials, with Custom III enrollment complete (data forthcoming in 2008).


XTNT has also filed its Investigational Device Exemption (IDE) to begin the Custom IV trial process, which includes interaction with the FDA re; eventual marketing in the US. The Custom NX system is expected to be available for commercial use in Europe in the 2nd half of 2008.

Report this Post Replies: 0 | Reply

Featured Broker Partners